Archivos del autor: Erika Erdmann

OPKO’s GeneDx Presenting on a Number of Topics at the 2016 ACMG Annual Clinical Genetics Meeting

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. announced today that its GeneDx subsidiary and business unit has been selected to give 11 platform talks and 18 poster presentations on a range of genetics-related topics at the 2016 American College of Medical Genetics and Genomics (ACMG) Annual Meeting. These presentations support GeneDx’s position as an industry leader in the wider genomics industry. […]

OPKO’s GeneDx Participating in the Molecular Medicine Tri-Conference 2016 in San Francisco

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) announced today that GeneDx was invited to participate in the Molecular Medicine Tri-Conference 2016, being held at the Moscone North Convention Center in San Francisco, California from March 6th – 11th, 2016, and will also be exhibiting at Booth 606. Wendy Chung, M.D. Ph.D., Associate Professor of Pediatrics and Medicine, Columbia University and Chief Scientific Officer, GeneDx, will participate in the […]

Study Demonstrates OPKO’s 4Kscore Test Reduces Unnecessary Prostate Biopsies While Improving Risk Prediction for Aggressive Prostate Cancer

4Kscore Test Results Significantly Influenced Physician-Patient Shared Decision-Making in Clinical Practice and Led to a 64.6% Reduction in Prostate Biopsies MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) announced today the results of a study for the 4Kscore® Test’s clinical utility in reducing the number of prostate biopsies performed, while increasing the probability of detecting aggressive prostate cancer […]

OPKO’s GeneDx to Present at Personalized Medicine World Conference

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) announced today that Marc D. Grodman, MD, Chief Executive Officer of its BioReference/GeneDx subsidiaries, will speak at this year’s Personalized Medicine World Conference, Silicon Valley. Dr. Grodman’s Presentation, titled “New Model of Clinical Genomics Collaboration”, will highlight a unique partnership between GeneDx and health systems to provide a complete genomic solution that facilitates improved […]

OPKO’s GeneDx Study of More Than 10,000 Individuals Tested with Multigene NGS Hereditary Cancer Panel Reveals New Risks

Largest Published Study to Date Supports Testing Changes and Development of New Treatment Options MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) through its subsidiary GeneDx, today announced results from the largest published study to date of patients who received hereditary genetic testing with Next Generation Sequencing (NGS) cancer panels. The study, “Pathogenic and Likely Pathogenic Variant Prevalence […]

OPKO’s GeneDx Subsidiary and North Shore-LIJ Health System Form Strategic Alliance for Genetic Testing

MIAMI, Dec. 14, 2015 /PRNewswire/ — The North Shore-LIJ Health System and OPKO Health, Inc. (NYSE: OPK) have formed a novel strategic alliance to provide genomic testing, molecular diagnostic testing and ancillary support services such as genetic counseling.  The scope of testing will cover all genetic disorders, including prenatal screening, pediatric and postnatal diagnosis, assessing risk for inherited cancer, and testing […]

OPKO’s GeneDx Study Demonstrates Whole Exome Sequencing Usefulness In Diagnosing Rare Disorders

Study reveals new disease causing genes MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) announced today through its subsidiary GeneDx, results from a retrospective review of molecular diagnostic testing by Whole Exome Sequencing (WES). The peer-reviewed study, “Clinical Application of Whole Exome Sequencing across Clinical Indications,” was published in the December 2015 issue of Genetics in Medicine. It is the largest data […]

OPKO 4Kscore Test Receives Category I CPT Code Approval

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) announced today that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Editorial Panel has granted a Category I CPT code for its 4Kscore® Test, the only blood test that accurately identifies an individual patient’s risk for aggressive prostate cancer. This important event upgrades the 4Kscore Test from a Category III Administrative code to a […]

OPKO Health Refinances Bio-Reference Laboratories Credit Facility

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced today that it has successfully closed on a new five-year $175.0 million secured revolving credit facility with JPMorgan Chase. The new facility replaced Bio-Reference Laboratories’ previous $120.0 million secured revolving credit facility. “We are excited to enter into a partnership with one of the world’s premier banking institutions, JPMorgan Chase,” commented Phillip Frost, MD, Chairman & […]

OPKO Health’s GeneDx Business Presenting at National Society of Genetic Counselors Annual Meeting

Focus is on Genetic Diagnosis of Rare Disease PITTSBURGH–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) announced today that GeneDx, a business unit of OPKO will be presenting at the National Society of Genetic Counselors (NSGC) 34th Annual Education Conference in Pittsburgh, PA. GeneDx staff and genetic counselors will participate at the conference as individual speakers, poster presenters and exhibitors. GeneDx is also sponsoring a networking […]

Powered by GlobalLink OneLink Software